key: cord-0946934-oj0q376t authors: Kickbusch, Ilona; Leung, Gabriel M; Shattock, Robin J title: Learning from crisis: building resilient systems to combat future pandemics date: 2021-07-01 journal: Lancet DOI: 10.1016/s0140-6736(21)00665-6 sha: fc3247aaedb25f82c5a23c5e0ffedb5918162804 doc_id: 946934 cord_uid: oj0q376t nan COVID-19 has accelerated medical research in the quest to understand this new pandemic threat, to answer public health questions, and to develop a vaccine that could allow a return to "normal" life. A spotlight has illuminated how evidence becomes policy, and the interface of politics and science, which encompasses ecological, financial, and social risks, among others. In a lecture delivered for the Academy of Medical Sciences on Nov 2, 2020, we examined the threat of future pandemics in the light of COVID-19, reviewing how to prepare, how to build resilient health systems, and what we can learn from coronavirus to combat pandemics of the future. Pandemics are not new; emerging and re-emerging infections present challenges to the global research community and are occurring with greater frequency as we impinge on more natural spaces and with increasing density of animal agriculture. Although many had predicted an influenza rather than a coronavirus pandemic, researchers have moved with unprecedented speed and coordination. Almost 12 months after the first cases were identified in Wuhan, what have we learnt about responding to a global pandemic? The vaccine race has created an explosion of effort in preclinical research. One of the greatest successes was the rapid online sharing of the SARS-CoV-2 genome. This facilitated simultaneous global efforts to develop vaccines around the world, enabling a rapid design phase, and many prototype vaccines entering preclinical assays in a matter of weeks after its publication. Previous evidence on the structural biology of SARS and MERS, particularly the stability and confirmation of the surface glycoprotein, allowed rapid design of CoV-2 glycoprotein immunogens, and many candidate vaccines moved quickly thanks to the dissemi nation of this information. As of May 14, 2021, there were 100 candidate vaccines in clinical evaluation, of which 20 were in phase 3 trials, and 184 candidates were in preclinical evaluation. New technologies such as RNA and protein subunits moved rapidly, thanks to synthetic production approaches, although these are not proven in the clinic and it will be interesting to see how they affect the pandemic. They are competing against established technologies such as viral vectors, which have also moved quickly. They will reach the clinic in different timeframes, and it remains to be seen if they will block only disease or also transmission. All candidate vaccines are designed for traditional intramuscular injection, and most for a two-dose schedule. As a respiratory virus, SARS-CoV-2 may require higher levels of mucosal immunity to block transmission; later efforts may need to go into mucosal vaccines in order to truly slow transmission rates. Vaccine design requires working slowly and carefully through several phases, usually one after the other. With COVID-19, some phases have been run in parallel to expedite the process. There is a perception of corners being cut that could cause issues around public acceptance. Although studies have happened more quickly, the numbers of individuals used in the three trial phases have been similar to those used in traditional vaccine development. However, we do not currently have long-term stability data for these products, nor do we know the duration of effectiveness for longer than the time of a clinical trial, which in this case has been contracted. The dual threats of Ebola and Zika drove the creation of the Coalition for Epidemic Preparedness Innovations (CEPI), which got the community thinking about how to respond to emerging and re-emerging diseases, and how responses should be financed. It can be unsustainable for pharmaceutical companies to meet a call to action each time there is an epidemic of a relatively small size; drug development requires massive investment, which is not always returned by the markets. Currently approved vaccines and those in phase 3 trials aim to modify disease by reducing morbidity and mortality; to reduce infection will be a significantly higher hurdle. The community is working first to reduce hospitalisation and severe disease but hopes that later vaccines will prevent all disease and control the pandemic. In the shorter term, lower efficacy against infection could mean more asymptomatic infections, with SARS-CoV-2 still widely circulating. One of the largest complications surrounding roll-out of any candidate vaccine will be understanding the duration of protection, and whether that is against disease or infection. If different vaccines have different timelines of efficacy and protection, monitoring and maintaining immunity will be complex for health systems. Ultimately, a well defined and easily operable set of correlates of protection, most likely at least including titre of neutralising antibody, will be crucial. In a first phase of roll-out, health workers and vulnerable populations should take priority. Not all vulnerable people respond well to vaccination so we may need to Delivery may be a challenge of public acceptance. Most people develop only mild or asymptomatic infection, so mass vaccination will be altruistic. It is also unlikely that early vaccines will offer 100% efficacy, with current trials to date powered for recognising just 50%-the seasonal influenza vaccine is 40-60% efficacious-which still has important public health benefits. Given these factors, people at risk of disease may accept a vaccine with substantial side-effects but those at lower risk less so. A survey of 14 countries between November, 2020, and February, 2021, found that almost 58% of participants would take a vaccine if offered, with an increase in willingness in nine countries over that period. In the UK, 77% of individuals indicated they would take the vaccine when available, up from 55% before the first vaccine was approved. Although worry over adverse effects has declined, many countries still have much to do about vaccine hesitancy to maximise vaccine take-up. A lot has been written about the difficulties of distribution, especially for some of the newer technologies, which present challenges for cold chain. These may end up being deployed in wealthy countries but not for less developed parts of the world. Concerns around advance purchase agreements are not unfounded, but these have provided the marketplace to enable pharmaceutical companies to respond to the virus, and strategies like the warp speed funding in the USA were instrumental for setting up large scale efficacy trials. To achieve global access, organisations like COVAX, the vaccines pillar of the Access to COVID-19 Tools Accelerator programme, offer pooled procurement, production, and equitable distribution of COVID-19 vaccines. The extent to which emerging viral variants might reduce efficacy of any of the currently approved vaccines is currently unclear. However, we are in the early days of this virus. Many people worldwide have not yet been exposed to the virus, and once levels of immunity grow, whether naturally or thanks to a vaccine, the impact of variants on vaccine efficacy might start to change. We need to be prepared to have next-generation variant vaccines ready should current vaccines become less effective over time. We learn through the acquisition and application of knowledge: the synthesis, acquisition, translation, and application of knowledge forms the backbone of medical progress. By examining the epidemiological evidence of two controversial non-pharmaceutical interventions-use of face masks and school closures-we can see lessons learned, and not learned, during the current pandemic. Over the course of 2020, the guidance changed on wearing of face masks. WHO initially recommended usage only in specific circumstances, but by mid-year, guidance had been updated to advise wide, general, and liberal usage. Until recently, the limited evidence base on the effectiveness of face masks largely focused on influenza in the community. A meta-analysis by Xiao and colleagues 2 included ten randomised controlled trials, and it found that universal mask wearing and increased hand hygiene could reduce confirmed influenza transmission by 10-20%. The picture for SARS-CoV-2 is different: a rapid review in June, 2020, 3 of face masks, eye protection, and physical distancing for SARS, MERS, and SARS-CoV-2 found a reduction by 75% in health-care settings and slightly less in community settings. Although this finding is probably an overestimation, it shows evidence for the potential benefit of such measures. More realistically, a more recent meta-analysis estimated that masks could reduce the risk of infection by between 6% and 15%. 4 In experimental work, researchers tried collecting exhaled samples of breath from outpatients with acute respiratory illness allocated to wear a mask or not. The exhalations were split into coarse diameter of greater than or less than 5 µm in order to distinguish droplet spread from aerosol spread. Looking at the four seasonal coronaviruses, a face mask was able to completely stop the collection of particles, whether greater or less than 5 µm. 5 Masks alone are probably necessary, useful, and insufficient: repeated large telephone surveys of public behaviour in Hong Kong suggest that from late January, 2020, onwards there was close to 100% mask wearing, 6 yet there have still been three substantial outbreaks, first in March and April, then in July and August, and since November into 2021. Other measures, including physical distancing must have also been responsible for bringing down these waves as masks were almost universally used throughout. It would be fallacious to argue that because masks are not 100% effective we should not wear them: even a 10% reduction would be useful. "Whether and how to open primary schools is not just a scientific and technocratic question. It is also an emotional and a moral one. Our sense of responsibility toward children-at the very least to protect them from the vicissitudes of life-including the poor decision making of adults who allow deadly infections to spiral out of control-is core to our humanity." 7 The World Bank Group Education Division modelled adverse effects of school closures from COVID-19, and found very serious impacts in four measured outcomeslearning adjusted outcomes of schooling, expected earnings, average Programme for International Student Assessment (PISA) scores, and share of students below PISA level-that traverse the life course of students. 8 Lockdowns involving repeated school closures would render the Sustainable Development Goal of halving the rate of learning poverty effectively unattainable. Data from France show that seasonal holidays prevent some 16-18% of influenza cases 9 and research in Hong Kong on the seasonal outbreak in 2008, 10 the H1N1 pandemic in 2009, 11 and the seasonal outbreak in 2018 12 suggests some impact for school closures during influenza pandemics, but only where schools close in time. Yet accumulating data for SARS-CoV-2 suggest lower susceptibility 13 as well as lesser severity 14 in the young. Relative infectiousness remains to be defined through large, unselected case-contact observational data in different contexts. In March, 2020, schools across 50 states in the USA closed, and research proposes that daily incidence was reduced by 62% and mortality by 58% 15 as a result. The methodology shows no adjustment for other nonpharmaceutical interventions, and the obvious correlation between these measures and school closures seems to have contributed to an overestimation. Given previous findings with influenza, this finding seems implausibly high. Effectiveness of school closures also depends on the underlying demographic structure and age-specific contact patterns. Different shapes of population pyramids and contact matrices between age groups that vary substantially between countries can translate into large variability of effect. 16 It remains unclear whether school closures work, and whether they work sufficiently to warrant the anticipated negative outcomes for children in education. With the availability of location-based functions on handheld devices and contact tracing apps, public health authorities should enhance understanding of population mobility and mixing patterns in order to more precisely target nonpharmaceutical interventions, including school closures, in future. Constructing contact matrices under different scenarios for their own communities should be prioritised, while ensuring privacy and confidentiality are respected. There are other key epidemiological lessons that we need to learn. The question of whether broad lockdowns, a focused protection approach, or the so-called Swedish approach of aiming for herd immunity are best in terms of health and economic protection deserves careful analysis, and the use of testing at different pandemic stages requires detailed study. Effective and acceptable ways of conducting contact tracing, including the necessary supportive infrastructure and digital apps, should be delineated in different contexts. In responding to a new virus, political mistakes will be made, but failure to respond is a much larger issue, and reveals important lessons that must be learned about the way we organise our societies. The pandemic cannot be seen in isolation, it is a component of a larger pattern of risk. We live in the Anthropocene, an era that is defined by the rise of human societies' unprecedented impact on the planet in the 20th century. 17 It involves an accumulation of risks-ecological, pandemic, financial, social, military, terrorist, biochemical, and informational-which are interconnected and feed off each other. The relationship between risk and power is unambiguous: who defines the risks, who takes political decisions, and who suffers the consequences. In the first response to COVID-19, there was the nationalist notion that we have to save ourselves and forget others. Global instruments and institutions failed in their response and an existing concern that the multilateral system was not up to dealing with such a global health challenge increased. The virus highlighted the fault lines in our societies and health systems, as well as in politics, multilateralism, and the international trading system. Europe and the USA engaged in magical thinkingthe dominant narrative meant that western countries did not feel the need to learn from others, particularly from Asian countries that responded quickly to COVID-19 and applied a range of measures for pandemic control. There are seven key areas on which to focus political lessons. While scientific progress has accelerated, technical and political solutions have been insufficient. The political determinants of health, the power relationships in global health, and the venues and the methods through which this power manifests itself need re-evaluation. The paradigmatic test case will be the equitable and fair access to a COVID-19 vaccine. The distribution of vaccines may be the defining global challenge of 2021. 18 Multilateralism is under scrutiny. The Global Health Security Index failed in its predictive function: countries ranked high for preparedness and response plans as well as public health institutions faced some of the greatest problems. The International Health Regulations, 19 adopted in 2005, proved insufficient. WHO lacked political and financial support. We face a standoff in relation to the World Trade Organization, and its agreement on trade-related aspects of intellectual property rights (TRIPS Agreement), which will play an important role in access to vaccines, therapeutics, and diagnostics. Populism and nationalism stand in the way of international solidarity. Western democratic systems were not prepared for emergency response. Asian democracies did better. We must ensure that the democratic processes and rights that we have in our societies are maintained, and involve communities. What kinds of literacies do we need, and how do we respond to an infodemic? We must explore how to better "pandemic-proof" our democracies. For the Global Health Security Index see https://www.ghsindex. org Viruses feed off political, economic, and social realities in our societies and pandemics take on features of those societies. The COVID-19 pandemic is estimated to push an additional 88 to 115 million people into extreme poverty in 2020, with the total rising to as many as 150 million by 2021, depending on the severity of the economic contraction. 20 Meanwhile, billionaires saw their net worth increase by half a trillion dollars. 21 Democracies must deal with the increasing inequalities over longer periods of time and the global system needs to deal with unequal vaccine distribution. The pandemic is not our only global risk. The concept of the global risk society was developed by Ulrich Beck, some years ago, and it is centred around manufactured uncertainties. In the Anthropocene we have created some risks, but we find it extremely difficult to live with the uncertainties they entail. They are hard to calculate, they are delocalised, and they run counter to the calculated type of risk in our insurance model as they cannot be easily compensated. The director general of WHO has said that no one is safe until all are safe. A new focus of cooperation must ensure the availability of public services, social protection, and universal health coverage. A global open-source systems pandemic alert system is being worked on for global good: knowledge must be shared. There is the wider issue of cyber biosecurity and new vulnerabilities that we will face, which should be seen in connection with the Green Deal and better social protection throughout the European Union. We must aim to build a more inclusive and digital society and a sustainable and green economy. COVAX is the largest multilateral agreement made since the Paris Climate Agreement, and both ventures call for collective action regarding a global public good. We are always preparing for the last crisis. Before this, we had influenza in mind, or Ebola, but no global pandemic alert system. How do we set up a better multisectoral system, and what then are the anticipatory triggers for action in different sectors? As a risk bubbles up in such a system, where we can respond quickly? Where do responsibilities align, and where we are willing to move forward in terms of financing collective preparedness? As we face a large transformation of our global system of risk, sharing a multisectoral approach has been proposed by the Global Preparedness Monitoring Board. A global framework treaty has been proposed by the EU. Multilateralism should be protected at the global level and the democratic model at the national level; the pandemic is testing our democratic way of life. 22 The reason for the failures did not happen overnight; they existed in the way we have organised our global cooperation over years, if not decades. We have failed to face up to tough decisions that we should have made in the face of a global risk society. There is no silver lining to a pandemic, but there may be silver linings in the lessons learned if we prepare with a new mind frame, responsible for one another and for the planet. Covid-19: global attitudes towards a COVID-19 vaccine Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-personal protective and environmental measures Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis Community use of facemasks and similar barriers to prevent respiratory illness such as COVID-19: a rapid scoping review Respiratory virus shedding in exhaled breath and efficacy of face masks Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study Reopening primary schools during the pandemic Simulating the potential impacts of the COVID-19 school closures on schooling and learning outcomes: a set of global estimates Estimating the impact of school closure on influenza transmission from Sentinel data Effects of school closures, 2008 winter influenza season, Hong Kong School closure and mitigation of pandemic (H1N1) 2009, Hong Kong Mitigation of influenza B epidemic with school closures Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China Association between statewide school closure and COVID-19 incidence and mortality in the US A global assessment of the impact of school closure in reducing COVID-19 spread Something new under the sun: an environmental history of the twentieth-century world (the global century series) Vaccine initiative now covers almost entire world, but not US or Russia Geneva: World Health Organization Poverty and shared prosperity 2020: reversals of fortune How billionaires got $637 billion richer during the coronavirus pandemic Graduate Institute of International and Development Studies All authors contributed equally to the conceptualisation and writing of the article. IK was mainly responsible for the political lessons section, GML for the public health lessons, and RJS for the vaccines section. IK is a member of the Global Preparedness Monitoring Board. GML and RJS declare no competing interests.